CA2025626A1 - Biodegradable stent - Google Patents
Biodegradable stentInfo
- Publication number
- CA2025626A1 CA2025626A1 CA002025626A CA2025626A CA2025626A1 CA 2025626 A1 CA2025626 A1 CA 2025626A1 CA 002025626 A CA002025626 A CA 002025626A CA 2025626 A CA2025626 A CA 2025626A CA 2025626 A1 CA2025626 A1 CA 2025626A1
- Authority
- CA
- Canada
- Prior art keywords
- stent
- ureteral
- weight
- terpolymer
- varies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/94—Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/048—Ureters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
Abstract
ABSTRACT OF THE DISCLOSURE
A biodegradable, biocompatible, resorbable infusion stent comprising a terpolymer of:
(a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone.
This invention includes a method for treating ureteral obstructions or impairments by utilizing a biodegradable, biocompatible, resorbable infusion stent, and a method for controlling the speed of resorption of the stent.
A biodegradable, biocompatible, resorbable infusion stent comprising a terpolymer of:
(a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone.
This invention includes a method for treating ureteral obstructions or impairments by utilizing a biodegradable, biocompatible, resorbable infusion stent, and a method for controlling the speed of resorption of the stent.
Description
B~oDEGRaDABL~ ~BNT
BACKGROUND OF THE INVENTION
1. FIELD OF THE INVENTION
This invention relates to the preparation of ureteral stents from biodegradable polymers of lactic acid.
BACKGROUND OF THE INVENTION
1. FIELD OF THE INVENTION
This invention relates to the preparation of ureteral stents from biodegradable polymers of lactic acid.
2. DESCRIPTIOM OF THE PRIOR ART
Ureteral stents are often used to maintain fluid drainage from the renal pelvis to the bladder when the ureter is obstructed or otherwise impaired, and also for providing ~upport to a collapsed or restricted ureter.
Very often, ureteral stents are positioned in a patient on a temporary basis to provide drainage from the kidney to the bladder following surgery. The stent is generally coiled or looped at opposite ends to prevent upward or downward migration from a predetermined position in the ureter caused by peristaltic action or other body motion that would impose forces on the stent to move it from its predetermined position.
Certain ureteral stents have the capability of infusing fluids into the kidney and are commonly referred to as "infusion stents".
In many situations where the ureteral stent is installed for short term usage, an additional surgical procedure must be employed to remove the stent after its purpose has been fulfilled.
.
A ureteral sten~ that is made of a biodegradable and biocompatible material would assure its safe and innocuous disappearance without the need for a second surgical procedure for its removal after it has completed its function.
Canadian Patent No. 808,731 to Fouty discloses the preparation of high molecular weight polylactides with an anionic coordination catalyst containing a divalent metal of Group II of the Periodic Table, to produce a polymer containing the divalent metal as part of the polylactide.
Either optical isomer of lactide may be used, and the lactide can be copolymerized with other cyclic esters having from 6 to 8 carbon atoms in the ring, such as glycolide or tetramethyl glycolide.
~.S. Patent No. 4,045,418 to Sinclair discloses thermally stable copolymers of optically inactive lactide and epsilon-caprolactone with a tin ester of carbo~ylic acid serving as a catalyst to produce throwaway thermoplastic objects that are environmentally attractive because thQy slowly degrade to harmless substances. Cyclic esters such as glycolide, lactide and the lactones are a}so disclosed as being used to produce thermoplastics. U.S. Patent No.
4,057,537 also to Sinclair discloses the copolymerization of glycolide with lactide and various lactones to form copolymers which are reported as use~ul in making absorbable 2 ~
sutures. Sinclair's primary objective is to produce a non-gummy, high impact, non-brittle, thermally stable copolymer of an optically active lactide and epsilon-caprolactone which can be fabricated into various thermoplastic objPcts that are disposable and environmentally attractive since ; they degrade into harmless substances.
U.s. Patent No. 3,844,987 to Clendinning et al, discloses shaped containers fabricated from biodegradable thermoplastic oxyalkanoyl polymers, such as epsilon-caprolactone polymers, and naturally occurring biodegradable substances to serve as containers in which to germinate and grow seed or seedlings.
U.S. Patent No. 3,636,956 to Schneider discloses copolymers of L(-)lactide with up to 35% glycolide for use in surgical applications such as sutures and ligatures.
U.S. Patent No. 3,739,773 to Schmitt et al, discloses polyglycolic acid or polyhydroxyacetic ester can be surgically used for a solid prosthesis or a protective gauze and is absorbable by living mammalian tissue.
U.S. Patent No. 3,736,646 to Schmitt discloses a copolymer containing 15 to 85 mole% of both glycolic and lactic acid can be formed into biodegradable surgical structures such as tubes or sheets or spun as filaments to prepare sutures.
U.S. Patent No. 4,300,565 to Rosensaft et al, discloses a method for producing sterile surgical articles from a synthetic absorbable copolymer formed by copolymerizing glycolide monomer with a cyclic ester monomer other than a glycolide, such as a lactone, oxalate or carbonate.
U.S. Patent No. 3,531,561 to Trehu discloses the use of high molecular weight polylactides extruded to form a surgical suture.
U.S. Patent No. 4,539,981 to Tunc discloses an absorbable bone fixation device made from a polymer of L(-)lactide with an inherent viscosity above 4.5.
U.S. Patent No. 4,181,983 to Kulkarni discloses an assimilable, porous, hydrophilic prosthesis composed of a polymer of hydroxycarboxylic acid, with the preferred polymer being a lactic acid.
U.S. Patent No. 4,137,921 to Okuzumi discloses the formation of highly crystalline, fiber-forming addition copolymers of lactide and glycolide having from 50 to 75%
glycolide. The lactide-glycolide addition copolymers are highly crystalline and useful in forming fibers for surgical sutures.
~2~2~
U.S. Patent No. 3,83g,927 to Wasserman et al, disclosas the formation of a high molecular weight 1-lactide/glycolide copolymer u~ing a stannous octoate catalyst. The copolymer may be extruded to form filaments useable as absorbable sutures.
European Patent Application No. 0204931 to Pertti et al, discloses a synthetic polymeric surgical osteosynthesis material absorbable by the body composed of such polymers as a polylactide.
Other patents of interest relating to the preparation of polylactides include U.S. Patent Nos. 2,703,316 to Schneider; 2,890,208 to Young et al; 2,36~,511 to Teeters;
Ureteral stents are often used to maintain fluid drainage from the renal pelvis to the bladder when the ureter is obstructed or otherwise impaired, and also for providing ~upport to a collapsed or restricted ureter.
Very often, ureteral stents are positioned in a patient on a temporary basis to provide drainage from the kidney to the bladder following surgery. The stent is generally coiled or looped at opposite ends to prevent upward or downward migration from a predetermined position in the ureter caused by peristaltic action or other body motion that would impose forces on the stent to move it from its predetermined position.
Certain ureteral stents have the capability of infusing fluids into the kidney and are commonly referred to as "infusion stents".
In many situations where the ureteral stent is installed for short term usage, an additional surgical procedure must be employed to remove the stent after its purpose has been fulfilled.
.
A ureteral sten~ that is made of a biodegradable and biocompatible material would assure its safe and innocuous disappearance without the need for a second surgical procedure for its removal after it has completed its function.
Canadian Patent No. 808,731 to Fouty discloses the preparation of high molecular weight polylactides with an anionic coordination catalyst containing a divalent metal of Group II of the Periodic Table, to produce a polymer containing the divalent metal as part of the polylactide.
Either optical isomer of lactide may be used, and the lactide can be copolymerized with other cyclic esters having from 6 to 8 carbon atoms in the ring, such as glycolide or tetramethyl glycolide.
~.S. Patent No. 4,045,418 to Sinclair discloses thermally stable copolymers of optically inactive lactide and epsilon-caprolactone with a tin ester of carbo~ylic acid serving as a catalyst to produce throwaway thermoplastic objects that are environmentally attractive because thQy slowly degrade to harmless substances. Cyclic esters such as glycolide, lactide and the lactones are a}so disclosed as being used to produce thermoplastics. U.S. Patent No.
4,057,537 also to Sinclair discloses the copolymerization of glycolide with lactide and various lactones to form copolymers which are reported as use~ul in making absorbable 2 ~
sutures. Sinclair's primary objective is to produce a non-gummy, high impact, non-brittle, thermally stable copolymer of an optically active lactide and epsilon-caprolactone which can be fabricated into various thermoplastic objPcts that are disposable and environmentally attractive since ; they degrade into harmless substances.
U.s. Patent No. 3,844,987 to Clendinning et al, discloses shaped containers fabricated from biodegradable thermoplastic oxyalkanoyl polymers, such as epsilon-caprolactone polymers, and naturally occurring biodegradable substances to serve as containers in which to germinate and grow seed or seedlings.
U.S. Patent No. 3,636,956 to Schneider discloses copolymers of L(-)lactide with up to 35% glycolide for use in surgical applications such as sutures and ligatures.
U.S. Patent No. 3,739,773 to Schmitt et al, discloses polyglycolic acid or polyhydroxyacetic ester can be surgically used for a solid prosthesis or a protective gauze and is absorbable by living mammalian tissue.
U.S. Patent No. 3,736,646 to Schmitt discloses a copolymer containing 15 to 85 mole% of both glycolic and lactic acid can be formed into biodegradable surgical structures such as tubes or sheets or spun as filaments to prepare sutures.
U.S. Patent No. 4,300,565 to Rosensaft et al, discloses a method for producing sterile surgical articles from a synthetic absorbable copolymer formed by copolymerizing glycolide monomer with a cyclic ester monomer other than a glycolide, such as a lactone, oxalate or carbonate.
U.S. Patent No. 3,531,561 to Trehu discloses the use of high molecular weight polylactides extruded to form a surgical suture.
U.S. Patent No. 4,539,981 to Tunc discloses an absorbable bone fixation device made from a polymer of L(-)lactide with an inherent viscosity above 4.5.
U.S. Patent No. 4,181,983 to Kulkarni discloses an assimilable, porous, hydrophilic prosthesis composed of a polymer of hydroxycarboxylic acid, with the preferred polymer being a lactic acid.
U.S. Patent No. 4,137,921 to Okuzumi discloses the formation of highly crystalline, fiber-forming addition copolymers of lactide and glycolide having from 50 to 75%
glycolide. The lactide-glycolide addition copolymers are highly crystalline and useful in forming fibers for surgical sutures.
~2~2~
U.S. Patent No. 3,83g,927 to Wasserman et al, disclosas the formation of a high molecular weight 1-lactide/glycolide copolymer u~ing a stannous octoate catalyst. The copolymer may be extruded to form filaments useable as absorbable sutures.
European Patent Application No. 0204931 to Pertti et al, discloses a synthetic polymeric surgical osteosynthesis material absorbable by the body composed of such polymers as a polylactide.
Other patents of interest relating to the preparation of polylactides include U.S. Patent Nos. 2,703,316 to Schneider; 2,890,208 to Young et al; 2,36~,511 to Teeters;
3,169,945 to Hostettler et al; 3,284,417 to Hostettler et al; 2,758,987 to Salzburg et al and Canadian Patent 779,291 to Kl~ine.
~2~2~
SUMMARY OF THE_INVENTION
The present invention is based upon the discovery of a biodegradable, biocompatible, resorbable infusion stent comprising a terpolymer of:
(a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone.
This invention is also based upon a method for treating ureteral obstruction or impairment by utilizing a biodegradable, biocompatible, resorbable infusion stent, and a method for controlling the rate of biodegradation of the stent.
DESCRIPTION OF ~HE PREFER~ED EMBODIME~TS
In accordance with the present invention, it has been foun* that a biocompatible, biodegradable, resorbable infusion stent can be made from a terpolymer of:
(a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone.
The inventive infusion stent has the following properties:
~,~2~
(i) a minimum tensile strength of at least about 500 p5i, preferably at least about 650 psi, (ii) an elongation greater than about 10~, preferably greater than about 100%, (iii) Shore A hardness of about 50 to lO0, preferably about 75 to 95.
In addition, the biodegradable stent is pliable, and can be fabricated or extruded into tubing with an inside diameter that can vary Prom about 0.050 to about 0.075 inches, and an outside diameter than can vary from about 0.075 to about 0.120 inches.
The inventive stent can be made transparent and is biocompatible. Because it is also biodegradable, the stent disintegrates in mammalian body tissue, within a Pew~weeks~
to a ~ew months, without interfering wi~h;urinary function.
The inventive stent can be fabricated~with a pliable curl set at each end by heat setting;~technlques, can be sterilized, and is capabIe of being compounded with radiopaque materials such as ~arium sulfate. The~stent should have a minlmum curl strength~of at least about 4~
grams, and a minimum break strength of about 1.7 pounds.
The stent can also be imprinted with biocompatible inks.
, .' ' ' ~' , It has been found that the controlling factor in the stiffness of the terpolymer composition used in making the stent is the amount of epsilon-caprolactone which can vary between about 15 and about 25 ~ by weight of the terpolymer composition. At about 15 weight % or less, the terpolymer composition becomes too stiff, and at about 25 weight % or higher, the composition becomes too pliable and weak to construct the stent. A 20 weight ~ caprolactone terpolymer is most preferred for its pliability characteristics.
The amounts of L(-)lactide can vary from about 45 to 85 weight %, preferably about 55 to 75 weight % and most preferably about 60 to 70 weight % of the terpolymer composition.
The amounts of glycolide can vary from about 5 to 50 weight ~, and preferably about 10 to 30 weight ~ of the terpolymer composition. The blending of those components produces a pliàble, transparent, thermoplastic elastomer that is biodegradable and biocompat1ble.
The mechanism of biodegradation o~ the inventive stent is essentially one of hydrolysis; that is, the destruction, decomposition, or alteration of the chemical composition of the stent by water to the point where the stent - 2~3~ 2~
disintegrates and is harmlessly excreted from the body in the urine. At the same time, certain portions of the stent which are in contact with the body tissues are resorbed into the tissues. For purposes of this invention, the tarms "biodegradation, biodegradable~' and the like are intended to also include resorption of the stent in the body tissues.
It has been found that when the glass transition temperature (Tg) of the biodegradable composition which comprises the stent is less than about 37C, biodegradation proceeds at a more rapid rate than when the Tg is about 37C
or greater.
Tg is defined as a second order transition temperature which results in a discontinuity of properties of a polymer composition. At the Tg, the polymer wlll change from a stif~ to a more flexible state, and its density and molecular free volume will increase.
Thus, when the Tg is less than about 37~C, the polymeric composition comprising the stent becomes more susceptible to penetration by body fluids and the time of biodegradation proceeds more rapidly.
The process of biodegradation of the stent begins from the time the stent is initially implanted between the kidney and bladder. However, the rate at which biodegradation occurs can be controlled to assure that the 2 ~ 2 ~
stent will function for the desired period of kime/ which can range from a ma~ter of weeks to two or three months or even longer as the requirement demands, based upon the individual condition and needs of the patient. Most preferably, the useful life of the stent, which is the time during which the stent continues to function and operate, will vary from about 3 to 7 weeks.
Factors which are influential in controlling the rate of biodegradation, which directly relate to the useful life of the stent, include the molecular weight of the stent composition and the amorphous nature of the stent composition. A reduction in molecular weight is indicative of biodegradation. The more amorphous the stent terpolymer composition is, the faster it will biodegrade.
~he inventive terpolymer should have a weight average molecular weight of about 20,000 to 1,000,000, preferably about 50,000 to 400,000, and is generally mvnomodal with respect to molecular weight distribution.
The inventive terpolymer can be melt processed without decomposing at temperatures of 230C and below.
~he terpolymer is thixotropic and most readily processable at temperatures from about 135 to 150C.
Important factors involved in tube fabrication include the shear rate in the extruder and temperature. The 5 preferred processing temperature for tube extrusion varies , .
.: .
2~2~
from about 135 to 150C. Processing at all conditions reduces the average molecular weight and affects all molecules similarly. The shear rate in the extruder should be maintained as low as possible to reduce the amount of melt fracture and molecular weight degradation. Thus, it is important in the processing to preferably maintain the shear rate in the extruder to about 500 to 1000 sec~1 to maintain physical properties as close to the original material as possible.
It is also desirable to incorporate or blend radiopaque materials such as barium sulfate with the terpolymer in amounts varying from about 5 to 30 weight %, preferably about 10 to 20 weight % of the terpolymer composltion. The barium sulfate is finely divided to a particle size which makes~ it homogeneous and compatible with the terpolym r, without affecting its light transmission propertie A
suitable particle size is where 99% of the particles pass through 325 mesh or a 45 micron opening.
Tbe present invention also provides a method for treating and remedying a ureteral obstruction or impairment with a ureteral stent without tha necessity for an additional surgical procedure to remove the stent aftPr it has performed its function and is no longer needed. The use of the inventive biodegradable, biocompatible and resorbable ureteral stent assures its safe and innocuous disappearance 2 ~ 2 ~
by biodegradation at a controlled and predictable rate after the stent has fulfilled its function. The controlled predictable rate of biodegradation is based upon such factors as molecular weight and extent of the amorphous nature of the terpolymer composition. Thus, the only surgical procedure necessary is the initial insertion and positioning of the ureteral stent between the kidney and the bladder. Removal is accomplished by biodegradation of the stent.
The following examples illustrate specific embodiments of the prPsent invention. In the examples and throughout the invention all parts and percentages are by weight, unless otherwise indicated.
~ - Example 1 STARTING MATERIALS
High-purity L(-)lactide is available from commercial sources, under the trademark Crystallization 3~ from Purac Inc., affiliated wlth CCA biochem bv. of The Netherlands, and under the trademark L-Lactide SY from Henley and Co., a subsidiary of Boehringer Ingelheim of Germany. Glycolide is available under the trademark Glycolide S~ from Henley and Co .
Epsilon-caprolactone having a purity above 99~ is purchased from commerical sources, such as Aldrich Company Catalog No. 16736-3, and is further purified by vacuum distillation through a Claisen head at 10 to 20 torr, to a water white cut at 90 to 115 C with a boiling point range of about ~2C. The distillation is discontinued when the pot supply is low and with the temperature rising at constant pressure. The distillate is stored under a moisture free nitrogen or argon atmosphere.
The catalyst, stannous octoate, is available from M~T
Chemicals, Rahway, NJ as an anhydrous solution. About 110 milliliters of dried CP (certified pure) or AP (analyæed pure) grade toluene and 20 milliliters of stannous octoate was pipetted into a 200 to 300 ml flask, equipped with eithe~ an argon or nitrogen purge and a Dean-Stark type trap that was capped with a Drierite drying tube. The empty apparatus was previously flame-dried and cooled under nitrogen. The toluene solution was brought to reflux under a nitrogen trickle and 10 milliliters was distilled, to insure that the last few milliliters were clear~
2~2~2~
Example 2 Preparation of Terpolymer 65 parts of L(-)lactide (L-lactide S~, Henley and Co.), 15 parts of glycolide (Glycolide S~, Henley and Co.), and 20 parts of puri~ied epsilon-caprolactone, (Aldrich Catalog No. 16736-3; Chemical Abstracts No. 502-44-3) were placed in an ampoule followed by the addition of 0.10 milliliters of a 20% stannous octoate solution in toluene.
The amount of stannous octoate catalyst solution was 0.10 milliliters per 100 grams of total lactide, glycolide and epsilon-caprolactone. The ampoule was evacuated with a vacuum pump for at least 10 minutes and sealed at its constriction. The contents were melted by placing the ampoule in a 140 to 160C oil bath, while mixing the melt by swirl~ing until the melt became viscou=. Heating continued for about 16 to 72 hours at 140 to 160C. The ampoule was~
removed from the oil bath, and cooled to room temperature.
The terpolymer product was removed from;the ampoule and stored in a desiccator. The terpolymer was transparent and nearly colorless. Its weight average molecular weight, as measured by gel permeation chromatography (GPC) was greater than 100,000.
The preparatory procedure was again repeated using different amounts of the components as tabulated in Tabls 1.
Taple 1 TERPOLYMER COMPOSITION, Weiaht %
Sample No. Lt-)lactide Glycolide EE~ilon-caprolactone 2 37~5 37.5 25 ~ 65 15 20 Each of the samples was then tested for various physical properties tabulated in Table 2.
Table 2 SUMMARY OF PHYSICAL PROPERTIES
SampleTensileta) Elongation~3) No.Strength, psi ~E~ Modulustb) Shore, A
1 ~ . 1627 596 506 51 3 13g3 35 8791 96(c) 3 1693(d) 40 9908 96 4(e) 1654 564 382 60 4558 275(f) 110,368 tShore Dj7s) 2 ~
Footnotes for Table 2 (a) Averag~ of S specimens, ASTM D-638, 70 mil thickness, crosshead speed 20 in./min. (b) Plastic or initial tangent modulus.
(c) Shore D: 54 (d) Crosshead speed 2 in./min.
(e) Tested at 37C.
(f) To failure, but 5~ to yield.
Example 3 Compression Moldin~ of Terpolymers Sheets of approximately 75 mil were compression molded in accordance with the following procedure:
60 grams of each terpolymer sample prepared in accordance with Example 2 were placed between silicone release paper in a polished, stainless steel hinged mold preheated in a press to the temperatures shown in Table 3.
Table 3 Sample No. Molding Tem~.F Platen Pressure (psi) 1 250 5,000 for 2 min.
10,000 for 3 min.
2 250 same as sample No. 1 4 266 " " " " "
330 20,000 for 1 min.
~2~2~
Contact pressure was maintained on the mold for approximately 2 to 5 minutes until the polymer flowed into the mold cavity. Platen pressure of 5,000 to 2,000 pounds was applied for 1 to 3 minutes as shown in Table 2. The mold was then put into a cooling press under the same platen pressure and held until cooled to room temperature. The sheet of polymer for each sample was removed from the mold and release paper and specimens were cut from the sheet for tensile tests, with the results tabulated in Table 4.
Table 4 ELASTOMER MODULI AT 100 AND 200% ELONGATION~
Sample No. 100% Modulus (psi) 200% Modulus ~psi~
3 ~ 446 489 2130 31~0 (a) Elastomer modulus is psi load at 100% and 200%
elongation.
Example 4 Characterization of Molecular Wei~ht and Thermal Properties A molecular weight analysis and thermal characterization of several samples of L(-)lactide/glycolide/
epsilon-caprolactone terpolymer with component ratios of 65/15/20 in parts by weight was conducted.
Molecular weight distribution and averages were determined using a Waters Model 150 C ALC/GPC SEC with a Model 820 data station and Maxima software. Operating parameters used to determine the molecular weight are listed in Table 5. Table 6 shows molecular weights calculated for the samples.
Table 5 O~erating Parameters for Molecular Weiaht AnalYsis - ~ Columns: 106-105-iO4-103 A ~ Styragel Solvent: Burdick ~ Jackson DIG Tetrahydrofuran Flow Rate: 1 ml/min Injection Volume: 100 ~ 1 Temperature: 23C ~RT) Nominal Concentration: 2 mg/ml Detector: Refractive Index Standards: Narrow distribution polystyrene 2 ~
Table 6 Molecular Weights of Terpolymer Samples Before and After Extrusion Into Tubina Description Mn~ lOOO's M~, lOOO's Mz, lOOO's M~Mn Before processing -Sample 1 106 197 3~2 1.88 Sample 2 145 310 591 2~14 Beginning of extrusion -Sample 1 86 173 300 2.01 Sample 2 104 228 526 2.18 Middle of extrusion -Sample 1 go 177 303 1.g7 Sample 2 103 204 364 1.98 End of extrusion -Sample 1 85 171 302 2.00 Sample 2 97 200 375 2.07 The terpolymers were monomodal with respect to molecular weight distribution. Although the polymers showed a decrease in molecular weight upon melt fabrication, the decrease was not significant in terms of loss of physical properties.
Thermal gravimetric analysis (TGA) and differential scanning calorimetry (DSC) were performed on the terpolymers. Inhomogeneity, as evidenced by melting points of monomers, or weight loss on programmed heating, as well lg 2~ 2 as melting points of homopolymers was not detectable. The terpolymers were pure and homogeneous, and contained at most ppm quantities of unreacted monomer. The terpolymer could be melt processed without decomposition at 230C and below.
The material was thixotropic (shear thinning) and processible at approximately 138-148C.
Example 5 Formation of Small Diameter Tubes A Brabender single screw 3/4 inch diameter extruder with 30 L/D was used with a die to manufacture small tube diameters. The take up device, a Univex Take-off from C.W.
Brabender, was placed aftPr a 6 foot water bath. The terpolymer composition of Example 4 was used. The initial processing temperatures for tube extrusion were 138 to 148~. The shear rate in the extruder was maintained in the range of 500 to 1000 sec.-1 to minimize the amount of melt fracture and molecular weight degradation. The molecular weights were determined using Maxima 820 GPC analysis, with results shown in Table 7 as follows:
Table 7 Molecular Weights Temperature Mn M~
oc Numbe~r Average Weiaht Average 5Unprocessed control 126412 295015 l3a 103062 2037~0 The extrusion temperature profile from the feed zone to the die was as follows:
Zone Tomperature C
1 (feed) 138 4 (die) - 148~ :
The terpolymer was extruded to produce a tube with an inside diameter of 0.072 inch and outside:diameter of 0.111 inch.
This test demonstrated that the biodegradable terpolymer can~
be extruded into small tubes with the desired~diameter using the processing conditions described. Important factors involved in tubo fabrication were shear~history and temperature. Processing at all conditions reduced the molecular weight averages and affected all molecules similarly. Thus, it was important in the processing to -: , , .
~32~
maintain the shear rate in the extr~lder at a minimum to maintain original material properties. The processing temperature also affected the final molecular weight. The higher the processing temperature, the lower the calculated molecular weight averages. Therefore, it is preferable to operate the extruder at the low end of the processing temperature range of the terpolymer (138 to 148C).
Example 6 Blending of Terpolymer with Barium Sulfate Followed by Extrusion A terpolymer having th~ same composition as that in Example 5 was melt blended with 12 percent by weight of small, micron size particulate BaS04 on a two roll mill at 280F. The BaS04 was homogeneous and compatible with the terpolymer. The terpolymer resin filled with the BaSO4 was then ground with dry ice and placed in an oven at 100F for 1 hour to remove excess moisture. To complete the drying, the material was placed in a vacuum oven at room temperature overnight.
The filled copolymer was extruded into a tube using a 3/4 inch Brabender extruder with 30:1 length to diameter ratio. Additional die parts were used for the small diameter requirements. A 6-foot water bath and a take up device followed the extruder to cool and control the size of the tubing. Air was also fed through the middle of the die to maintain the tube shape until the material cooled and established its own integrity. The final tube diameter was determined by balancing the extruder rpm, air pressure, and take up speed with the die dimensions. The processing temperatures used in the fabrication of the tubing were:
Temperature Profile (F) Tl (feed) T2 T3 T4 (die) The tubing was able to be heat-set into approximately a 1 inch diameter curl by looping it around or within a mandril, heating the curled tubing to 4~-50C
(108-122F) and cooling it in place. The curl, thus formed, promptly returned to its position when straightened.
The molecular weight of the BaS04 filled terpolymer tubing was then determined. The weight average-, number average-, and Z-average molecular weights, respectively, were 260,000;~lS2,000; and 442,000. This demonstrated that the terpolymers can be processed to retain useful properties for applications as a stent. The tubing extrudates were of good quality - smooth, homogeneous, tough, and elastic.
Preliminary results indicated that the tubing embrittled somewhat after 3 weeks in contact with aqueous fluids.
Although it was still somewhat pliable, ductile failure occurred upon handling and bending. At that stage, the Mu, Mn~ and Mz, respectively, were 27,600; 10,400; and 51,623. The polydispersity (M~Mn) was 2.65, which is a slight increase over the value of 2. n for the unexposed terpolymer (see Table 7).
Differential scanning calorimetry indicated substantial hydrolysis and degradation. After 6-7 weeks the walls of the tubing appeared much thinner. The terpolymer tubing became softer and somewhat fibrous, and shredded easily into soft pieces.
Although the composition comprising the inventive biodegradable, biocompatible, resorbable ureteral stent has been disclosed in the context of a terpolymer of L(-)lactide, glycolide and epilson-caprolactone, other equivalent compositions are also contemplated as being suitable compdsitions for preparing the stent.
Thus, it is contemplated that D(-)lactide~ the internally optically inactive meso lactide and the optically inactive racemic or D,L-lactide can be substituted for the L(-)lactide. It is also contemplated that delta-valerolactone can be substituted for epilson-caprolactone.
A discussion of the mechanism of biodegradation of the~e com~ounds in the form of films is disclosed in Pitt et 2 ~ 6 al "Alphatic Polyesters II. The Degradation of Poly (DL-Lactide), Poly (Epilson-Caprolactone)~ and Their Co-Polymers In Vivo", BIOMATERIALS, pages 215-220, (Vol. II, October 1981), which is incorporated by reference herein.
~2~2~
SUMMARY OF THE_INVENTION
The present invention is based upon the discovery of a biodegradable, biocompatible, resorbable infusion stent comprising a terpolymer of:
(a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone.
This invention is also based upon a method for treating ureteral obstruction or impairment by utilizing a biodegradable, biocompatible, resorbable infusion stent, and a method for controlling the rate of biodegradation of the stent.
DESCRIPTION OF ~HE PREFER~ED EMBODIME~TS
In accordance with the present invention, it has been foun* that a biocompatible, biodegradable, resorbable infusion stent can be made from a terpolymer of:
(a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone.
The inventive infusion stent has the following properties:
~,~2~
(i) a minimum tensile strength of at least about 500 p5i, preferably at least about 650 psi, (ii) an elongation greater than about 10~, preferably greater than about 100%, (iii) Shore A hardness of about 50 to lO0, preferably about 75 to 95.
In addition, the biodegradable stent is pliable, and can be fabricated or extruded into tubing with an inside diameter that can vary Prom about 0.050 to about 0.075 inches, and an outside diameter than can vary from about 0.075 to about 0.120 inches.
The inventive stent can be made transparent and is biocompatible. Because it is also biodegradable, the stent disintegrates in mammalian body tissue, within a Pew~weeks~
to a ~ew months, without interfering wi~h;urinary function.
The inventive stent can be fabricated~with a pliable curl set at each end by heat setting;~technlques, can be sterilized, and is capabIe of being compounded with radiopaque materials such as ~arium sulfate. The~stent should have a minlmum curl strength~of at least about 4~
grams, and a minimum break strength of about 1.7 pounds.
The stent can also be imprinted with biocompatible inks.
, .' ' ' ~' , It has been found that the controlling factor in the stiffness of the terpolymer composition used in making the stent is the amount of epsilon-caprolactone which can vary between about 15 and about 25 ~ by weight of the terpolymer composition. At about 15 weight % or less, the terpolymer composition becomes too stiff, and at about 25 weight % or higher, the composition becomes too pliable and weak to construct the stent. A 20 weight ~ caprolactone terpolymer is most preferred for its pliability characteristics.
The amounts of L(-)lactide can vary from about 45 to 85 weight %, preferably about 55 to 75 weight % and most preferably about 60 to 70 weight % of the terpolymer composition.
The amounts of glycolide can vary from about 5 to 50 weight ~, and preferably about 10 to 30 weight ~ of the terpolymer composition. The blending of those components produces a pliàble, transparent, thermoplastic elastomer that is biodegradable and biocompat1ble.
The mechanism of biodegradation o~ the inventive stent is essentially one of hydrolysis; that is, the destruction, decomposition, or alteration of the chemical composition of the stent by water to the point where the stent - 2~3~ 2~
disintegrates and is harmlessly excreted from the body in the urine. At the same time, certain portions of the stent which are in contact with the body tissues are resorbed into the tissues. For purposes of this invention, the tarms "biodegradation, biodegradable~' and the like are intended to also include resorption of the stent in the body tissues.
It has been found that when the glass transition temperature (Tg) of the biodegradable composition which comprises the stent is less than about 37C, biodegradation proceeds at a more rapid rate than when the Tg is about 37C
or greater.
Tg is defined as a second order transition temperature which results in a discontinuity of properties of a polymer composition. At the Tg, the polymer wlll change from a stif~ to a more flexible state, and its density and molecular free volume will increase.
Thus, when the Tg is less than about 37~C, the polymeric composition comprising the stent becomes more susceptible to penetration by body fluids and the time of biodegradation proceeds more rapidly.
The process of biodegradation of the stent begins from the time the stent is initially implanted between the kidney and bladder. However, the rate at which biodegradation occurs can be controlled to assure that the 2 ~ 2 ~
stent will function for the desired period of kime/ which can range from a ma~ter of weeks to two or three months or even longer as the requirement demands, based upon the individual condition and needs of the patient. Most preferably, the useful life of the stent, which is the time during which the stent continues to function and operate, will vary from about 3 to 7 weeks.
Factors which are influential in controlling the rate of biodegradation, which directly relate to the useful life of the stent, include the molecular weight of the stent composition and the amorphous nature of the stent composition. A reduction in molecular weight is indicative of biodegradation. The more amorphous the stent terpolymer composition is, the faster it will biodegrade.
~he inventive terpolymer should have a weight average molecular weight of about 20,000 to 1,000,000, preferably about 50,000 to 400,000, and is generally mvnomodal with respect to molecular weight distribution.
The inventive terpolymer can be melt processed without decomposing at temperatures of 230C and below.
~he terpolymer is thixotropic and most readily processable at temperatures from about 135 to 150C.
Important factors involved in tube fabrication include the shear rate in the extruder and temperature. The 5 preferred processing temperature for tube extrusion varies , .
.: .
2~2~
from about 135 to 150C. Processing at all conditions reduces the average molecular weight and affects all molecules similarly. The shear rate in the extruder should be maintained as low as possible to reduce the amount of melt fracture and molecular weight degradation. Thus, it is important in the processing to preferably maintain the shear rate in the extruder to about 500 to 1000 sec~1 to maintain physical properties as close to the original material as possible.
It is also desirable to incorporate or blend radiopaque materials such as barium sulfate with the terpolymer in amounts varying from about 5 to 30 weight %, preferably about 10 to 20 weight % of the terpolymer composltion. The barium sulfate is finely divided to a particle size which makes~ it homogeneous and compatible with the terpolym r, without affecting its light transmission propertie A
suitable particle size is where 99% of the particles pass through 325 mesh or a 45 micron opening.
Tbe present invention also provides a method for treating and remedying a ureteral obstruction or impairment with a ureteral stent without tha necessity for an additional surgical procedure to remove the stent aftPr it has performed its function and is no longer needed. The use of the inventive biodegradable, biocompatible and resorbable ureteral stent assures its safe and innocuous disappearance 2 ~ 2 ~
by biodegradation at a controlled and predictable rate after the stent has fulfilled its function. The controlled predictable rate of biodegradation is based upon such factors as molecular weight and extent of the amorphous nature of the terpolymer composition. Thus, the only surgical procedure necessary is the initial insertion and positioning of the ureteral stent between the kidney and the bladder. Removal is accomplished by biodegradation of the stent.
The following examples illustrate specific embodiments of the prPsent invention. In the examples and throughout the invention all parts and percentages are by weight, unless otherwise indicated.
~ - Example 1 STARTING MATERIALS
High-purity L(-)lactide is available from commercial sources, under the trademark Crystallization 3~ from Purac Inc., affiliated wlth CCA biochem bv. of The Netherlands, and under the trademark L-Lactide SY from Henley and Co., a subsidiary of Boehringer Ingelheim of Germany. Glycolide is available under the trademark Glycolide S~ from Henley and Co .
Epsilon-caprolactone having a purity above 99~ is purchased from commerical sources, such as Aldrich Company Catalog No. 16736-3, and is further purified by vacuum distillation through a Claisen head at 10 to 20 torr, to a water white cut at 90 to 115 C with a boiling point range of about ~2C. The distillation is discontinued when the pot supply is low and with the temperature rising at constant pressure. The distillate is stored under a moisture free nitrogen or argon atmosphere.
The catalyst, stannous octoate, is available from M~T
Chemicals, Rahway, NJ as an anhydrous solution. About 110 milliliters of dried CP (certified pure) or AP (analyæed pure) grade toluene and 20 milliliters of stannous octoate was pipetted into a 200 to 300 ml flask, equipped with eithe~ an argon or nitrogen purge and a Dean-Stark type trap that was capped with a Drierite drying tube. The empty apparatus was previously flame-dried and cooled under nitrogen. The toluene solution was brought to reflux under a nitrogen trickle and 10 milliliters was distilled, to insure that the last few milliliters were clear~
2~2~2~
Example 2 Preparation of Terpolymer 65 parts of L(-)lactide (L-lactide S~, Henley and Co.), 15 parts of glycolide (Glycolide S~, Henley and Co.), and 20 parts of puri~ied epsilon-caprolactone, (Aldrich Catalog No. 16736-3; Chemical Abstracts No. 502-44-3) were placed in an ampoule followed by the addition of 0.10 milliliters of a 20% stannous octoate solution in toluene.
The amount of stannous octoate catalyst solution was 0.10 milliliters per 100 grams of total lactide, glycolide and epsilon-caprolactone. The ampoule was evacuated with a vacuum pump for at least 10 minutes and sealed at its constriction. The contents were melted by placing the ampoule in a 140 to 160C oil bath, while mixing the melt by swirl~ing until the melt became viscou=. Heating continued for about 16 to 72 hours at 140 to 160C. The ampoule was~
removed from the oil bath, and cooled to room temperature.
The terpolymer product was removed from;the ampoule and stored in a desiccator. The terpolymer was transparent and nearly colorless. Its weight average molecular weight, as measured by gel permeation chromatography (GPC) was greater than 100,000.
The preparatory procedure was again repeated using different amounts of the components as tabulated in Tabls 1.
Taple 1 TERPOLYMER COMPOSITION, Weiaht %
Sample No. Lt-)lactide Glycolide EE~ilon-caprolactone 2 37~5 37.5 25 ~ 65 15 20 Each of the samples was then tested for various physical properties tabulated in Table 2.
Table 2 SUMMARY OF PHYSICAL PROPERTIES
SampleTensileta) Elongation~3) No.Strength, psi ~E~ Modulustb) Shore, A
1 ~ . 1627 596 506 51 3 13g3 35 8791 96(c) 3 1693(d) 40 9908 96 4(e) 1654 564 382 60 4558 275(f) 110,368 tShore Dj7s) 2 ~
Footnotes for Table 2 (a) Averag~ of S specimens, ASTM D-638, 70 mil thickness, crosshead speed 20 in./min. (b) Plastic or initial tangent modulus.
(c) Shore D: 54 (d) Crosshead speed 2 in./min.
(e) Tested at 37C.
(f) To failure, but 5~ to yield.
Example 3 Compression Moldin~ of Terpolymers Sheets of approximately 75 mil were compression molded in accordance with the following procedure:
60 grams of each terpolymer sample prepared in accordance with Example 2 were placed between silicone release paper in a polished, stainless steel hinged mold preheated in a press to the temperatures shown in Table 3.
Table 3 Sample No. Molding Tem~.F Platen Pressure (psi) 1 250 5,000 for 2 min.
10,000 for 3 min.
2 250 same as sample No. 1 4 266 " " " " "
330 20,000 for 1 min.
~2~2~
Contact pressure was maintained on the mold for approximately 2 to 5 minutes until the polymer flowed into the mold cavity. Platen pressure of 5,000 to 2,000 pounds was applied for 1 to 3 minutes as shown in Table 2. The mold was then put into a cooling press under the same platen pressure and held until cooled to room temperature. The sheet of polymer for each sample was removed from the mold and release paper and specimens were cut from the sheet for tensile tests, with the results tabulated in Table 4.
Table 4 ELASTOMER MODULI AT 100 AND 200% ELONGATION~
Sample No. 100% Modulus (psi) 200% Modulus ~psi~
3 ~ 446 489 2130 31~0 (a) Elastomer modulus is psi load at 100% and 200%
elongation.
Example 4 Characterization of Molecular Wei~ht and Thermal Properties A molecular weight analysis and thermal characterization of several samples of L(-)lactide/glycolide/
epsilon-caprolactone terpolymer with component ratios of 65/15/20 in parts by weight was conducted.
Molecular weight distribution and averages were determined using a Waters Model 150 C ALC/GPC SEC with a Model 820 data station and Maxima software. Operating parameters used to determine the molecular weight are listed in Table 5. Table 6 shows molecular weights calculated for the samples.
Table 5 O~erating Parameters for Molecular Weiaht AnalYsis - ~ Columns: 106-105-iO4-103 A ~ Styragel Solvent: Burdick ~ Jackson DIG Tetrahydrofuran Flow Rate: 1 ml/min Injection Volume: 100 ~ 1 Temperature: 23C ~RT) Nominal Concentration: 2 mg/ml Detector: Refractive Index Standards: Narrow distribution polystyrene 2 ~
Table 6 Molecular Weights of Terpolymer Samples Before and After Extrusion Into Tubina Description Mn~ lOOO's M~, lOOO's Mz, lOOO's M~Mn Before processing -Sample 1 106 197 3~2 1.88 Sample 2 145 310 591 2~14 Beginning of extrusion -Sample 1 86 173 300 2.01 Sample 2 104 228 526 2.18 Middle of extrusion -Sample 1 go 177 303 1.g7 Sample 2 103 204 364 1.98 End of extrusion -Sample 1 85 171 302 2.00 Sample 2 97 200 375 2.07 The terpolymers were monomodal with respect to molecular weight distribution. Although the polymers showed a decrease in molecular weight upon melt fabrication, the decrease was not significant in terms of loss of physical properties.
Thermal gravimetric analysis (TGA) and differential scanning calorimetry (DSC) were performed on the terpolymers. Inhomogeneity, as evidenced by melting points of monomers, or weight loss on programmed heating, as well lg 2~ 2 as melting points of homopolymers was not detectable. The terpolymers were pure and homogeneous, and contained at most ppm quantities of unreacted monomer. The terpolymer could be melt processed without decomposition at 230C and below.
The material was thixotropic (shear thinning) and processible at approximately 138-148C.
Example 5 Formation of Small Diameter Tubes A Brabender single screw 3/4 inch diameter extruder with 30 L/D was used with a die to manufacture small tube diameters. The take up device, a Univex Take-off from C.W.
Brabender, was placed aftPr a 6 foot water bath. The terpolymer composition of Example 4 was used. The initial processing temperatures for tube extrusion were 138 to 148~. The shear rate in the extruder was maintained in the range of 500 to 1000 sec.-1 to minimize the amount of melt fracture and molecular weight degradation. The molecular weights were determined using Maxima 820 GPC analysis, with results shown in Table 7 as follows:
Table 7 Molecular Weights Temperature Mn M~
oc Numbe~r Average Weiaht Average 5Unprocessed control 126412 295015 l3a 103062 2037~0 The extrusion temperature profile from the feed zone to the die was as follows:
Zone Tomperature C
1 (feed) 138 4 (die) - 148~ :
The terpolymer was extruded to produce a tube with an inside diameter of 0.072 inch and outside:diameter of 0.111 inch.
This test demonstrated that the biodegradable terpolymer can~
be extruded into small tubes with the desired~diameter using the processing conditions described. Important factors involved in tubo fabrication were shear~history and temperature. Processing at all conditions reduced the molecular weight averages and affected all molecules similarly. Thus, it was important in the processing to -: , , .
~32~
maintain the shear rate in the extr~lder at a minimum to maintain original material properties. The processing temperature also affected the final molecular weight. The higher the processing temperature, the lower the calculated molecular weight averages. Therefore, it is preferable to operate the extruder at the low end of the processing temperature range of the terpolymer (138 to 148C).
Example 6 Blending of Terpolymer with Barium Sulfate Followed by Extrusion A terpolymer having th~ same composition as that in Example 5 was melt blended with 12 percent by weight of small, micron size particulate BaS04 on a two roll mill at 280F. The BaS04 was homogeneous and compatible with the terpolymer. The terpolymer resin filled with the BaSO4 was then ground with dry ice and placed in an oven at 100F for 1 hour to remove excess moisture. To complete the drying, the material was placed in a vacuum oven at room temperature overnight.
The filled copolymer was extruded into a tube using a 3/4 inch Brabender extruder with 30:1 length to diameter ratio. Additional die parts were used for the small diameter requirements. A 6-foot water bath and a take up device followed the extruder to cool and control the size of the tubing. Air was also fed through the middle of the die to maintain the tube shape until the material cooled and established its own integrity. The final tube diameter was determined by balancing the extruder rpm, air pressure, and take up speed with the die dimensions. The processing temperatures used in the fabrication of the tubing were:
Temperature Profile (F) Tl (feed) T2 T3 T4 (die) The tubing was able to be heat-set into approximately a 1 inch diameter curl by looping it around or within a mandril, heating the curled tubing to 4~-50C
(108-122F) and cooling it in place. The curl, thus formed, promptly returned to its position when straightened.
The molecular weight of the BaS04 filled terpolymer tubing was then determined. The weight average-, number average-, and Z-average molecular weights, respectively, were 260,000;~lS2,000; and 442,000. This demonstrated that the terpolymers can be processed to retain useful properties for applications as a stent. The tubing extrudates were of good quality - smooth, homogeneous, tough, and elastic.
Preliminary results indicated that the tubing embrittled somewhat after 3 weeks in contact with aqueous fluids.
Although it was still somewhat pliable, ductile failure occurred upon handling and bending. At that stage, the Mu, Mn~ and Mz, respectively, were 27,600; 10,400; and 51,623. The polydispersity (M~Mn) was 2.65, which is a slight increase over the value of 2. n for the unexposed terpolymer (see Table 7).
Differential scanning calorimetry indicated substantial hydrolysis and degradation. After 6-7 weeks the walls of the tubing appeared much thinner. The terpolymer tubing became softer and somewhat fibrous, and shredded easily into soft pieces.
Although the composition comprising the inventive biodegradable, biocompatible, resorbable ureteral stent has been disclosed in the context of a terpolymer of L(-)lactide, glycolide and epilson-caprolactone, other equivalent compositions are also contemplated as being suitable compdsitions for preparing the stent.
Thus, it is contemplated that D(-)lactide~ the internally optically inactive meso lactide and the optically inactive racemic or D,L-lactide can be substituted for the L(-)lactide. It is also contemplated that delta-valerolactone can be substituted for epilson-caprolactone.
A discussion of the mechanism of biodegradation of the~e com~ounds in the form of films is disclosed in Pitt et 2 ~ 6 al "Alphatic Polyesters II. The Degradation of Poly (DL-Lactide), Poly (Epilson-Caprolactone)~ and Their Co-Polymers In Vivo", BIOMATERIALS, pages 215-220, (Vol. II, October 1981), which is incorporated by reference herein.
Claims (27)
- THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS
l. A biodegradable, biocompatible, resorbable, ureteral stent comprising a terpolymer of:
(a) L(-)lactide (b) glycolide, and (c) epsilon-caprolactone, wherein said ureteral stent has:
(i) a tensile strength of at least about 500 psi (ii) an elongation greater than about 10%, and (iii) Shore A hardness of about 50 to 100. - 2. The ureteral stent of claim 1, wherein the epsilon-caprolactone varies from about 15 to 25 weight %.
- 3. The ureteral stent of claim l, wherein the L(-) lactide varies from about 45 to 85 weight %.
- 4. The ureteral stent of claim 1, wherein the glycolide varies from about 5 to 50 weight %.
- 5. The ureteral stent of claim l, also including about 5 to 30 weight % of a radiopaque material
- 6. The ureteral stent of claim 5, wherein said radiopaque material is finely divided barium sulfate.
- 7. The ureteral stent of claim 1, wherein the modulus varies from about 6000 to 7000 psi.
- 8. The ureteral stent of claim l, bendable into a pliable curl set at each end.
- 9. The ureteral stent of claim 1, sterilizable and capable of compounding with radiopaque materials.
- 10. The ureteral stent of claim 1, in transparent form.
- 11. The ureteral stent of claim 1, wherein the terpolymer has a weight average molecular weight varying from about 20,000 to 1,000,000.
- 12. A method for treating ureteral obstruction or impairment in a mammalian host by implanting therein a biodegradable, biocompatible resorbable stent between the kidney and the bladder, said stent having the following properties:
(i) a tensile strength of at least about 500 psi, (ii) an elongation greater than about 10%, and (iii) Shore A hardness of about 50 to 100. - 13. The method of claim 12, wherein the stent comprises a terpolymer of:
(a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone. - 14. The method of claim 12, wherein the stent has the following properties: .
(a) tensile strength greater than 1000 psi, (b) elongation greater than 100%, and (c) Shore A hardness of about 75 to 95. - 15. The method of claim 12, wherein the stent comprises of terpolymer of:
(a) L(-)lactide, (b) glycolide, and (c) epsilon-caprolactone. - 16. The method of claim 15, wherein the L(-)lactide varies from about 45 to 85 weight %.
- 17. The method of claim 15, wherein the glycolide varies from about 5 to 50 weight %.
- 18. The method of claim 15, wherein the epsilon-caprolactone varies from about 15 to 25 weight %.
- 19. The ureteral stent of claim 1, wherein the terpolymer has a melt process decomposition temperature greater than or equal to about 230°C.
- 20. The ureteral stent of claim 1, wherein the terpolymer has a tube extrusion processing temperature that varies from about 135 to 150°C.
- 21. The ureteral stent of claim 11, wherein, the terpolymer has a weight average molecular weight of about 50,000 to 400,000.
- 22. The method of claim 12, wherein said stent comprises a polymeric material having a weight average molecular weight varying from about 50,000 to 400,000.
- 23. A method for controlling the time of biodegradation in mammalian body tissue of a biodegradable, biocompatible, resorbable ureteral stent, by implanting a polymeric stent in mammalian body tissue, wherein said polymeric stent is biodegradable, biocompatible and resorbable and has the following properties:
(a) a tensile strength of at least about 500 psi, (b) an elongation greater than about 10%, and (c) Shore A hardness of about 50 to 100, and controlling the rate of biodegradation of said polymeric stent from a few weeks to a few months, by varying the molecular weight of the polymer composition comprising the stent, from a weight average molecular weight of about 50,000 to about 1,000,000. - 24. The method of claim 23, wherein the weight average molecular weight of said polymeric stent varies from about 50,000 to about 400,000.
- 25. An article of manufacture comprising a biocompatible, resorbable ureteral stent made of a biodegradable polymeric composition, wherein said stent is used for treating ureteral obstruction and has the following properties:
(i) a tensile strength of at least about 500 psi, (ii) an elongation greater than about 10%, and (iii) Shore A hardness of about 50 to 100. - 26. The stent of claim 25, wherein the weight average molecular weight of said polymeric composition varies from about 50,000 to 400,000.
- 27. The stent of claim 25: having a minimum curl strength of at least about 4 grams and a minimum break strength of about 1.7 pounds.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/414,651 US5085629A (en) | 1988-10-06 | 1989-09-27 | Biodegradable stent |
US414,651 | 1989-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2025626A1 true CA2025626A1 (en) | 1991-03-28 |
Family
ID=23642348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002025626A Abandoned CA2025626A1 (en) | 1989-09-27 | 1990-09-18 | Biodegradable stent |
Country Status (5)
Country | Link |
---|---|
US (1) | US5085629A (en) |
EP (1) | EP0420541A3 (en) |
JP (1) | JPH03205059A (en) |
AU (1) | AU633361B2 (en) |
CA (1) | CA2025626A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464450A (en) * | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
US5551954A (en) | 1991-10-04 | 1996-09-03 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5762625A (en) * | 1992-09-08 | 1998-06-09 | Kabushikikaisha Igaki Iryo Sekkei | Luminal stent and device for inserting luminal stent |
US5817100A (en) * | 1994-02-07 | 1998-10-06 | Kabushikikaisya Igaki Iryo Sekkei | Stent device and stent supplying system |
US6045568A (en) * | 1991-03-08 | 2000-04-04 | Igaki; Keiji | Luminal stent, holding structure therefor and device for attaching luminal stent |
USRE38653E1 (en) * | 1991-03-08 | 2004-11-16 | Kabushikikaisha Igaki Iryo Sekkei | Luminal stent, holding structure therefor and device for attaching luminal stent |
US6981985B2 (en) | 2002-01-22 | 2006-01-03 | Boston Scientific Scimed, Inc. | Stent bumper struts |
US7060089B2 (en) | 2002-01-23 | 2006-06-13 | Boston Scientific Scimed, Inc. | Multi-layer stent |
US7572287B2 (en) | 2001-10-25 | 2009-08-11 | Boston Scientific Scimed, Inc. | Balloon expandable polymer stent with reduced elastic recoil |
Families Citing this family (308)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6740731B2 (en) * | 1988-08-08 | 2004-05-25 | Cargill Dow Polymers Llc | Degradation control of environmentally degradable disposable materials |
US6323307B1 (en) | 1988-08-08 | 2001-11-27 | Cargill Dow Polymers, Llc | Degradation control of environmentally degradable disposable materials |
US5502158A (en) * | 1988-08-08 | 1996-03-26 | Ecopol, Llc | Degradable polymer composition |
US5444113A (en) * | 1988-08-08 | 1995-08-22 | Ecopol, Llc | End use applications of biodegradable polymers |
DE68922497T2 (en) * | 1988-08-24 | 1995-09-14 | Marvin J Slepian | ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS. |
US5749915A (en) * | 1988-08-24 | 1998-05-12 | Focal, Inc. | Polymeric endoluminal paving process |
US5080665A (en) * | 1990-07-06 | 1992-01-14 | American Cyanamid Company | Deformable, absorbable surgical device |
USRE38711E1 (en) * | 1991-03-08 | 2005-03-15 | Kabushikikaisha Igaki Iryo Sekkei | Luminal stent, holding structure therefor and device for attaching luminal stent |
US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5489297A (en) * | 1992-01-27 | 1996-02-06 | Duran; Carlos M. G. | Bioprosthetic heart valve with absorbable stent |
CA2087132A1 (en) * | 1992-01-31 | 1993-08-01 | Michael S. Williams | Stent capable of attachment within a body lumen |
WO1993015787A1 (en) * | 1992-02-12 | 1993-08-19 | Chandler Jerry W | Biodegradable stent |
US5599352A (en) * | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
FR2689388B1 (en) * | 1992-04-07 | 1999-07-16 | Celsa Lg | PERFECTIONALLY RESORBABLE BLOOD FILTER. |
US5599291A (en) * | 1993-01-04 | 1997-02-04 | Menlo Care, Inc. | Softening expanding ureteral stent |
DE69412474T2 (en) * | 1993-04-28 | 1998-12-17 | Focal Inc | DEVICE, PRODUCT AND USE REGARDING INTRALUMINAL PHOTOTHERMO MOLDING |
US5925065A (en) * | 1993-06-11 | 1999-07-20 | United States Surgical Corporation | Coated gut suture |
US5425949A (en) * | 1993-06-11 | 1995-06-20 | United States Surgical Corporation | Bioabsorbable copolymer and coating composition containing same |
US5939191A (en) * | 1993-06-11 | 1999-08-17 | United States Surgical Corporation | Coated gut suture |
CA2123647C (en) * | 1993-06-11 | 2007-04-17 | Steven L. Bennett | Bioabsorbable copolymer and coating composition containing same |
FI942170A (en) * | 1993-06-15 | 1994-12-16 | Esa Viherkoski | Tubular device for holding the urethra open |
US5531716A (en) * | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
WO1995010989A1 (en) * | 1993-10-19 | 1995-04-27 | Scimed Life Systems, Inc. | Intravascular stent pump |
NL9400519A (en) * | 1994-03-31 | 1995-11-01 | Rijksuniversiteit | Intravascular polymeric stent. |
DK63894A (en) * | 1994-06-06 | 1996-01-08 | Meadox Medicals Inc | Stent catheter and method for making such a stent catheter |
US5629077A (en) * | 1994-06-27 | 1997-05-13 | Advanced Cardiovascular Systems, Inc. | Biodegradable mesh and film stent |
US20020032298A1 (en) * | 1994-07-22 | 2002-03-14 | Bennett Steven L. | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
US6339130B1 (en) * | 1994-07-22 | 2002-01-15 | United States Surgical Corporation | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
US5578662A (en) | 1994-07-22 | 1996-11-26 | United States Surgical Corporation | Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom |
US6102045A (en) * | 1994-07-22 | 2000-08-15 | Premier Laser Systems, Inc. | Method and apparatus for lowering the intraocular pressure of an eye |
US5704907A (en) * | 1994-07-22 | 1998-01-06 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
US5520631A (en) * | 1994-07-22 | 1996-05-28 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
US20020055786A1 (en) * | 1994-08-16 | 2002-05-09 | Anthony Atala | Reconstruction of urological structures with polymeric matrices |
US5593403A (en) * | 1994-09-14 | 1997-01-14 | Scimed Life Systems Inc. | Method for modifying a stent in an implanted site |
EP1304085A3 (en) * | 1994-09-16 | 2004-01-21 | Ethicon Endo-Surgery, Inc. | Biodegradable tissue marking device |
US5707385A (en) * | 1994-11-16 | 1998-01-13 | Advanced Cardiovascular Systems, Inc. | Drug loaded elastic membrane and method for delivery |
US5562653A (en) * | 1994-11-16 | 1996-10-08 | Hercules Incorporated | Medical devices composed of low ceiling temperature polymers |
US5637113A (en) * | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5728152A (en) * | 1995-06-07 | 1998-03-17 | St. Jude Medical, Inc. | Bioresorbable heart valve support |
US5747637A (en) * | 1995-09-07 | 1998-05-05 | Mitsui Toatsu Chemicals, Inc. | Bioabsorbable polymer and process for preparing the same |
FI954565A0 (en) | 1995-09-27 | 1995-09-27 | Biocon Oy | Biologically applied polymeric material to the implant and foil preparation |
JPH11514546A (en) | 1995-11-01 | 1999-12-14 | セント ジュード メディカル,インコーポレイテッド | Bioabsorbable annuloplasty prosthesis |
CA2195384C (en) * | 1996-01-19 | 2007-06-05 | Kung Liu Cheng | Absorbable polymer blends and surgical articles fabricated therefrom |
US5718862A (en) * | 1996-04-24 | 1998-02-17 | Hercules Incorporated | Secondary shaping of ionically crosslinked polymer compositions for medical devices |
US5684051A (en) * | 1996-04-24 | 1997-11-04 | Hercules Incorporated | Medical devices with improved elastic response |
US5670161A (en) * | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
US6060534A (en) | 1996-07-11 | 2000-05-09 | Scimed Life Systems, Inc. | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US6368356B1 (en) | 1996-07-11 | 2002-04-09 | Scimed Life Systems, Inc. | Medical devices comprising hydrogel polymers having improved mechanical properties |
US5820918A (en) * | 1996-07-11 | 1998-10-13 | Hercules Incorporated | Medical devices containing in-situ generated medical compounds |
US7351421B2 (en) * | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
US10028851B2 (en) * | 1997-04-15 | 2018-07-24 | Advanced Cardiovascular Systems, Inc. | Coatings for controlling erosion of a substrate of an implantable medical device |
US8172897B2 (en) * | 1997-04-15 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Polymer and metal composite implantable medical devices |
US6240616B1 (en) * | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US6776792B1 (en) | 1997-04-24 | 2004-08-17 | Advanced Cardiovascular Systems Inc. | Coated endovascular stent |
US6174330B1 (en) * | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US6245103B1 (en) | 1997-08-01 | 2001-06-12 | Schneider (Usa) Inc | Bioabsorbable self-expanding stent |
US6340367B1 (en) * | 1997-08-01 | 2002-01-22 | Boston Scientific Scimed, Inc. | Radiopaque markers and methods of using the same |
US5980564A (en) * | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
US6186985B1 (en) | 1997-10-03 | 2001-02-13 | Boston Scientific Corporation | Gastro-intestinal tube with dissolvable support bolster |
ATE248615T1 (en) * | 1997-10-31 | 2003-09-15 | Childrens Medical Center | BLADDER RECONSTRUCTION |
US6270464B1 (en) * | 1998-06-22 | 2001-08-07 | Artemis Medical, Inc. | Biopsy localization method and device |
US5957975A (en) * | 1997-12-15 | 1999-09-28 | The Cleveland Clinic Foundation | Stent having a programmed pattern of in vivo degradation |
US6626939B1 (en) * | 1997-12-18 | 2003-09-30 | Boston Scientific Scimed, Inc. | Stent-graft with bioabsorbable structural support |
US5962007A (en) * | 1997-12-19 | 1999-10-05 | Indigo Medical, Inc. | Use of a multi-component coil medical construct |
US6001117A (en) * | 1998-03-19 | 1999-12-14 | Indigo Medical, Inc. | Bellows medical construct and apparatus and method for using same |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US6241762B1 (en) * | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US7179289B2 (en) * | 1998-03-30 | 2007-02-20 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US6177094B1 (en) | 1998-04-30 | 2001-01-23 | United States Surgical Corporation | Bioabsorbable blends and coating composition containing same |
US20020058882A1 (en) * | 1998-06-22 | 2002-05-16 | Artemis Medical, Incorporated | Biopsy localization method and device |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US6371904B1 (en) * | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6356782B1 (en) * | 1998-12-24 | 2002-03-12 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
DK173680B1 (en) | 1999-02-10 | 2001-06-11 | Coloplast As | ostomy Prop |
WO2000056376A1 (en) * | 1999-03-25 | 2000-09-28 | Metabolix, Inc. | Medical devices and applications of polyhydroxyalkanoate polymers |
KR100321647B1 (en) * | 1999-04-01 | 2002-01-23 | 윤율로 | A decomposable ureter stent in a living body, and a process for preparing the same. |
US6464723B1 (en) | 1999-04-22 | 2002-10-15 | Advanced Cardiovascular Systems, Inc. | Radiopaque stents |
US20040167634A1 (en) * | 1999-05-26 | 2004-08-26 | Anthony Atala | Prosthetic kidney and its use for treating kidney disease |
US6368346B1 (en) | 1999-06-03 | 2002-04-09 | American Medical Systems, Inc. | Bioresorbable stent |
US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6585757B1 (en) | 1999-09-15 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Endovascular stent with radiopaque spine |
US6312474B1 (en) | 1999-09-15 | 2001-11-06 | Bio-Vascular, Inc. | Resorbable implant materials |
US6334868B1 (en) | 1999-10-08 | 2002-01-01 | Advanced Cardiovascular Systems, Inc. | Stent cover |
EP1229901B1 (en) * | 1999-11-17 | 2009-03-18 | Boston Scientific Limited | Microfabricated devices for the delivery of molecules into a carrier fluid |
US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
US6602287B1 (en) | 1999-12-08 | 2003-08-05 | Advanced Cardiovascular Systems, Inc. | Stent with anti-thrombogenic coating |
US6702849B1 (en) | 1999-12-13 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers |
US6338739B1 (en) | 1999-12-22 | 2002-01-15 | Ethicon, Inc. | Biodegradable stent |
US7169187B2 (en) | 1999-12-22 | 2007-01-30 | Ethicon, Inc. | Biodegradable stent |
US7875283B2 (en) * | 2000-04-13 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Biodegradable polymers for use with implantable medical devices |
US8109994B2 (en) * | 2003-01-10 | 2012-02-07 | Abbott Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US6652579B1 (en) | 2000-06-22 | 2003-11-25 | Advanced Cardiovascular Systems, Inc. | Radiopaque stent |
IL137090A (en) * | 2000-06-29 | 2010-04-15 | Pentech Medical Devices Ltd | Polymeric stent |
JP2004508884A (en) * | 2000-09-25 | 2004-03-25 | コヒージョン テクノロジーズ, インコーポレイテッド | Resorbable anastomotic stent and plug |
US20050165428A1 (en) * | 2000-09-25 | 2005-07-28 | Franco Kenneth L. | Absorable surgical structure |
US20040106988A1 (en) * | 2000-09-29 | 2004-06-03 | Summers David P. | Resorbable prosthesis for medical treatment |
DE20122506U1 (en) | 2000-10-16 | 2005-12-08 | Conor Medsystems, Inc., Menlo Park | Expandable medical device for delivering a beneficial agent |
US6783793B1 (en) * | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
KR100408458B1 (en) * | 2000-12-27 | 2003-12-06 | 한국과학기술연구원 | Porous Scaffolds for Tissue Engineering made from the Biodegradable Glycolide/ε-Caprolactone Copolymer |
US20040220660A1 (en) * | 2001-02-05 | 2004-11-04 | Shanley John F. | Bioresorbable stent with beneficial agent reservoirs |
US7266687B2 (en) * | 2001-02-16 | 2007-09-04 | Motorola, Inc. | Method and apparatus for storing and distributing encryption keys |
US6913765B2 (en) | 2001-03-21 | 2005-07-05 | Scimed Life Systems, Inc. | Controlling resorption of bioresorbable medical implant material |
US6719804B2 (en) * | 2001-04-02 | 2004-04-13 | Scimed Life Systems, Inc. | Medical stent and related methods |
US20030069629A1 (en) * | 2001-06-01 | 2003-04-10 | Jadhav Balkrishna S. | Bioresorbable medical devices |
US7201940B1 (en) * | 2001-06-12 | 2007-04-10 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for thermal spray processing of medical devices |
US6565659B1 (en) * | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
US7842083B2 (en) * | 2001-08-20 | 2010-11-30 | Innovational Holdings, Llc. | Expandable medical device with improved spatial distribution |
US6747121B2 (en) * | 2001-09-05 | 2004-06-08 | Synthes (Usa) | Poly(L-lactide-co-glycolide) copolymers, methods for making and using same, and devices containing same |
US7989018B2 (en) * | 2001-09-17 | 2011-08-02 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
US7285304B1 (en) | 2003-06-25 | 2007-10-23 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
US6863683B2 (en) | 2001-09-19 | 2005-03-08 | Abbott Laboratoris Vascular Entities Limited | Cold-molding process for loading a stent onto a stent delivery system |
US6620202B2 (en) | 2001-10-16 | 2003-09-16 | Scimed Life Systems, Inc. | Medical stent with variable coil and related methods |
AU2002340463A1 (en) * | 2001-11-16 | 2003-06-10 | Children's Medical Center Corporation | Augmentation of organ function |
US8328877B2 (en) * | 2002-03-19 | 2012-12-11 | Boston Scientific Scimed, Inc. | Stent retention element and related methods |
US20050019404A1 (en) * | 2003-06-30 | 2005-01-27 | Hsing-Wen Sung | Drug-eluting biodegradable stent |
US7211114B2 (en) * | 2002-08-26 | 2007-05-01 | The Trustees Of Columbia University In The City Of New York | Endoscopic gastric bypass |
JP4809605B2 (en) * | 2002-10-28 | 2011-11-09 | タイコ ヘルスケア グループ エルピー | Bioabsorbable adhesive compound |
US20060271168A1 (en) * | 2002-10-30 | 2006-11-30 | Klaus Kleine | Degradable medical device |
EP1415671A1 (en) | 2002-11-01 | 2004-05-06 | Polyganics B.V. | Biodegradable drains for medical applications |
US7435255B1 (en) | 2002-11-13 | 2008-10-14 | Advnaced Cardiovascular Systems, Inc. | Drug-eluting stent and methods of making |
US7144422B1 (en) | 2002-11-13 | 2006-12-05 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent and methods of making the same |
US7285287B2 (en) * | 2002-11-14 | 2007-10-23 | Synecor, Llc | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
US20040098106A1 (en) * | 2002-11-14 | 2004-05-20 | Williams Michael S. | Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents |
US6887266B2 (en) | 2002-11-14 | 2005-05-03 | Synecor, Llc | Endoprostheses and methods of manufacture |
US20040098090A1 (en) * | 2002-11-14 | 2004-05-20 | Williams Michael S. | Polymeric endoprosthesis and method of manufacture |
US8435550B2 (en) * | 2002-12-16 | 2013-05-07 | Abbot Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US7758881B2 (en) * | 2004-06-30 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US7105018B1 (en) * | 2002-12-30 | 2006-09-12 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent cover and method of use |
US7144588B2 (en) | 2003-01-17 | 2006-12-05 | Synovis Life Technologies, Inc. | Method of preventing surgical adhesions |
US20040260386A1 (en) * | 2003-01-31 | 2004-12-23 | Shalaby Shalaby W. | Absorbable / biodegradable tubular stent and methods of making the same |
US6932930B2 (en) * | 2003-03-10 | 2005-08-23 | Synecor, Llc | Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same |
US6929663B2 (en) * | 2003-03-26 | 2005-08-16 | Boston Scientific Scimed, Inc. | Longitudinally expanding medical device |
AU2004238229B2 (en) * | 2003-05-08 | 2007-07-12 | Tepha, Inc. | Polyhydroxyalkanoate medical textiles and fibers |
EP1643968A1 (en) * | 2003-05-30 | 2006-04-12 | ALZA Corporation | Implantable elastomeric depot compositions, uses thereof and method of manufacturing |
US7186789B2 (en) * | 2003-06-11 | 2007-03-06 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings |
WO2005007195A1 (en) * | 2003-07-08 | 2005-01-27 | Tepha, Inc. | Poly-4-hydroxybutyrate matrices for sustained drug delivery |
WO2005020825A1 (en) * | 2003-08-22 | 2005-03-10 | Tepha, Inc. | Polyhydroxyalkanoate nerve regeneration devices |
US7198675B2 (en) * | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
US20050107867A1 (en) * | 2003-11-17 | 2005-05-19 | Taheri Syde A. | Temporary absorbable venous occlusive stent and superficial vein treatment method |
US20050214339A1 (en) * | 2004-03-29 | 2005-09-29 | Yiwen Tang | Biologically degradable compositions for medical applications |
US9498322B2 (en) * | 2004-03-31 | 2016-11-22 | Cook Medical Technologies Llc | Multi-portion endoluminal prosthesis |
US7582110B2 (en) * | 2004-04-13 | 2009-09-01 | Cook Incorporated | Implantable frame with variable compliance |
JP4772669B2 (en) * | 2004-04-19 | 2011-09-14 | 川澄化学工業株式会社 | Artificial dura mater and method for producing the same |
WO2005104992A1 (en) * | 2004-04-26 | 2005-11-10 | Bioduct Llc | Stent for avascular meniscal repair and regeneration |
US7820732B2 (en) * | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
US20050288481A1 (en) * | 2004-04-30 | 2005-12-29 | Desnoyer Jessica R | Design of poly(ester amides) for the control of agent-release from polymeric compositions |
US8568469B1 (en) | 2004-06-28 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Stent locking element and a method of securing a stent on a delivery system |
US8241554B1 (en) | 2004-06-29 | 2012-08-14 | Advanced Cardiovascular Systems, Inc. | Method of forming a stent pattern on a tube |
US8747879B2 (en) * | 2006-04-28 | 2014-06-10 | Advanced Cardiovascular Systems, Inc. | Method of fabricating an implantable medical device to reduce chance of late inflammatory response |
US7971333B2 (en) * | 2006-05-30 | 2011-07-05 | Advanced Cardiovascular Systems, Inc. | Manufacturing process for polymetric stents |
US8747878B2 (en) | 2006-04-28 | 2014-06-10 | Advanced Cardiovascular Systems, Inc. | Method of fabricating an implantable medical device by controlling crystalline structure |
US8778256B1 (en) | 2004-09-30 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Deformation of a polymer tube in the fabrication of a medical article |
US20060020330A1 (en) * | 2004-07-26 | 2006-01-26 | Bin Huang | Method of fabricating an implantable medical device with biaxially oriented polymers |
US7731890B2 (en) * | 2006-06-15 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Methods of fabricating stents with enhanced fracture toughness |
PT1778305E (en) * | 2004-08-03 | 2010-07-27 | Tepha Inc | Non-curling polyhydroxyalkanoate sutures |
US8980300B2 (en) | 2004-08-05 | 2015-03-17 | Advanced Cardiovascular Systems, Inc. | Plasticizers for coating compositions |
US20060041102A1 (en) * | 2004-08-23 | 2006-02-23 | Advanced Cardiovascular Systems, Inc. | Implantable devices comprising biologically absorbable polymers having constant rate of degradation and methods for fabricating the same |
US9283099B2 (en) * | 2004-08-25 | 2016-03-15 | Advanced Cardiovascular Systems, Inc. | Stent-catheter assembly with a releasable connection for stent retention |
US20060052822A1 (en) * | 2004-08-31 | 2006-03-09 | Mirizzi Michael S | Apparatus and material composition for permanent occlusion of a hollow anatomical structure |
US7229471B2 (en) * | 2004-09-10 | 2007-06-12 | Advanced Cardiovascular Systems, Inc. | Compositions containing fast-leaching plasticizers for improved performance of medical devices |
US7875233B2 (en) | 2004-09-30 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Method of fabricating a biaxially oriented implantable medical device |
US8043553B1 (en) | 2004-09-30 | 2011-10-25 | Advanced Cardiovascular Systems, Inc. | Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article |
US8173062B1 (en) | 2004-09-30 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Controlled deformation of a polymer tube in fabricating a medical article |
AU2005296053B2 (en) * | 2004-10-18 | 2011-03-10 | Covidien Lp | Compression anastomosis device and method |
CN102525591B (en) | 2005-01-25 | 2014-12-10 | 泰科医疗集团有限合伙公司 | Structures for permanent occlusion of a hollow anatomical structure |
DE602006016915D1 (en) * | 2005-01-28 | 2010-10-28 | Tepha Inc | EMBOLIZATION USING POLY-4-HYDROXYBUTYRATE PARTICLES |
CA2596885C (en) * | 2005-02-04 | 2014-07-08 | Poly-Med, Inc. | Fiber-reinforced composite absorbable endoureteral stent |
US8083805B2 (en) * | 2005-08-16 | 2011-12-27 | Poly-Med, Inc. | Absorbable endo-urological devices and applications therefor |
US8083806B2 (en) | 2005-02-04 | 2011-12-27 | Poly-Med, Inc. | Radiation and radiochemically sterilized fiber-reinforced, composite urinogenital stents |
US20060216431A1 (en) * | 2005-03-28 | 2006-09-28 | Kerrigan Cameron K | Electrostatic abluminal coating of a stent crimped on a balloon catheter |
US20060224226A1 (en) * | 2005-03-31 | 2006-10-05 | Bin Huang | In-vivo radial orientation of a polymeric implantable medical device |
US20060276882A1 (en) * | 2005-04-11 | 2006-12-07 | Cook Incorporated | Medical device including remodelable material attached to frame |
US7381048B2 (en) * | 2005-04-12 | 2008-06-03 | Advanced Cardiovascular Systems, Inc. | Stents with profiles for gripping a balloon catheter and molds for fabricating stents |
US7291166B2 (en) * | 2005-05-18 | 2007-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric stent patterns |
US7622070B2 (en) * | 2005-06-20 | 2009-11-24 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing an implantable polymeric medical device |
US20060292690A1 (en) * | 2005-06-22 | 2006-12-28 | Cesco Bioengineering Co., Ltd. | Method of making cell growth surface |
US7658880B2 (en) * | 2005-07-29 | 2010-02-09 | Advanced Cardiovascular Systems, Inc. | Polymeric stent polishing method and apparatus |
US7297758B2 (en) * | 2005-08-02 | 2007-11-20 | Advanced Cardiovascular Systems, Inc. | Method for extending shelf-life of constructs of semi-crystallizable polymers |
US20070038292A1 (en) * | 2005-08-09 | 2007-02-15 | Moise Danielpour | Bio-absorbable stent |
US9592362B2 (en) | 2005-08-10 | 2017-03-14 | Ethicon, Inc. | Method of making absorbable microtubes and the product thereof |
US20070038290A1 (en) * | 2005-08-15 | 2007-02-15 | Bin Huang | Fiber reinforced composite stents |
US7476245B2 (en) * | 2005-08-16 | 2009-01-13 | Advanced Cardiovascular Systems, Inc. | Polymeric stent patterns |
US9248034B2 (en) | 2005-08-23 | 2016-02-02 | Advanced Cardiovascular Systems, Inc. | Controlled disintegrating implantable medical devices |
US20070045255A1 (en) * | 2005-08-23 | 2007-03-01 | Klaus Kleine | Laser induced plasma machining with an optimized process gas |
US20070045252A1 (en) * | 2005-08-23 | 2007-03-01 | Klaus Kleine | Laser induced plasma machining with a process gas |
US20070050009A1 (en) * | 2005-08-30 | 2007-03-01 | Aiden Flanagan | Bioabsorbable stent |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US20070148251A1 (en) * | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
US20070156230A1 (en) | 2006-01-04 | 2007-07-05 | Dugan Stephen R | Stents with radiopaque markers |
US20070160672A1 (en) * | 2006-01-06 | 2007-07-12 | Vipul Bhupendra Dave | Methods of making bioabsorbable drug delivery devices comprised of solvent cast films |
US20070162110A1 (en) * | 2006-01-06 | 2007-07-12 | Vipul Bhupendra Dave | Bioabsorbable drug delivery devices |
US7951185B1 (en) | 2006-01-06 | 2011-05-31 | Advanced Cardiovascular Systems, Inc. | Delivery of a stent at an elevated temperature |
US20070158880A1 (en) * | 2006-01-06 | 2007-07-12 | Vipul Bhupendra Dave | Methods of making bioabsorbable drug delivery devices comprised of solvent cast tubes |
US20070179219A1 (en) * | 2006-01-31 | 2007-08-02 | Bin Huang | Method of fabricating an implantable medical device using gel extrusion and charge induced orientation |
US20070203569A1 (en) * | 2006-02-24 | 2007-08-30 | Robert Burgermeister | Implantable device formed from polymer blends having modified molecular structures |
US7964210B2 (en) * | 2006-03-31 | 2011-06-21 | Abbott Cardiovascular Systems Inc. | Degradable polymeric implantable medical devices with a continuous phase and discrete phase |
US9017361B2 (en) * | 2006-04-20 | 2015-04-28 | Covidien Lp | Occlusive implant and methods for hollow anatomical structure |
US20070254012A1 (en) * | 2006-04-28 | 2007-11-01 | Ludwig Florian N | Controlled degradation and drug release in stents |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
AU2007249229B2 (en) * | 2006-05-12 | 2013-05-23 | Cardinal Health 529, Llc | Balloon expandable bioabsorbable drug eluting flexible stent |
US7761968B2 (en) * | 2006-05-25 | 2010-07-27 | Advanced Cardiovascular Systems, Inc. | Method of crimping a polymeric stent |
US8752268B2 (en) | 2006-05-26 | 2014-06-17 | Abbott Cardiovascular Systems Inc. | Method of making stents with radiopaque markers |
US7951194B2 (en) | 2006-05-26 | 2011-05-31 | Abbott Cardiovascular Sysetms Inc. | Bioabsorbable stent with radiopaque coating |
US7842737B2 (en) | 2006-09-29 | 2010-11-30 | Abbott Cardiovascular Systems Inc. | Polymer blend-bioceramic composite implantable medical devices |
US8343530B2 (en) * | 2006-05-30 | 2013-01-01 | Abbott Cardiovascular Systems Inc. | Polymer-and polymer blend-bioceramic composite implantable medical devices |
US7959940B2 (en) * | 2006-05-30 | 2011-06-14 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical devices |
US20070282434A1 (en) * | 2006-05-30 | 2007-12-06 | Yunbing Wang | Copolymer-bioceramic composite implantable medical devices |
US20080058916A1 (en) * | 2006-05-31 | 2008-03-06 | Bin Huang | Method of fabricating polymeric self-expandable stent |
US20070282433A1 (en) * | 2006-06-01 | 2007-12-06 | Limon Timothy A | Stent with retention protrusions formed during crimping |
US20070281073A1 (en) * | 2006-06-01 | 2007-12-06 | Gale David C | Enhanced adhesion of drug delivery coatings on stents |
US8034287B2 (en) * | 2006-06-01 | 2011-10-11 | Abbott Cardiovascular Systems Inc. | Radiation sterilization of medical devices |
US8486135B2 (en) | 2006-06-01 | 2013-07-16 | Abbott Cardiovascular Systems Inc. | Implantable medical devices fabricated from branched polymers |
US20080124372A1 (en) * | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
US20070286941A1 (en) * | 2006-06-13 | 2007-12-13 | Bin Huang | Surface treatment of a polymeric stent |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8048448B2 (en) * | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8535372B1 (en) | 2006-06-16 | 2013-09-17 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with prohealing layer |
US8333000B2 (en) | 2006-06-19 | 2012-12-18 | Advanced Cardiovascular Systems, Inc. | Methods for improving stent retention on a balloon catheter |
US20070290412A1 (en) * | 2006-06-19 | 2007-12-20 | John Capek | Fabricating a stent with selected properties in the radial and axial directions |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US9072820B2 (en) * | 2006-06-26 | 2015-07-07 | Advanced Cardiovascular Systems, Inc. | Polymer composite stent with polymer particles |
US8128688B2 (en) * | 2006-06-27 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Carbon coating on an implantable device |
US20070299511A1 (en) * | 2006-06-27 | 2007-12-27 | Gale David C | Thin stent coating |
US7794776B1 (en) | 2006-06-29 | 2010-09-14 | Abbott Cardiovascular Systems Inc. | Modification of polymer stents with radiation |
US9265865B2 (en) * | 2006-06-30 | 2016-02-23 | Boston Scientific Scimed, Inc. | Stent having time-release indicator |
US7740791B2 (en) * | 2006-06-30 | 2010-06-22 | Advanced Cardiovascular Systems, Inc. | Method of fabricating a stent with features by blow molding |
US20080009938A1 (en) * | 2006-07-07 | 2008-01-10 | Bin Huang | Stent with a radiopaque marker and method for making the same |
US7823263B2 (en) | 2006-07-11 | 2010-11-02 | Abbott Cardiovascular Systems Inc. | Method of removing stent islands from a stent |
US7757543B2 (en) | 2006-07-13 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Radio frequency identification monitoring of stents |
US7998404B2 (en) * | 2006-07-13 | 2011-08-16 | Advanced Cardiovascular Systems, Inc. | Reduced temperature sterilization of stents |
US20080014244A1 (en) * | 2006-07-13 | 2008-01-17 | Gale David C | Implantable medical devices and coatings therefor comprising physically crosslinked block copolymers |
US7794495B2 (en) * | 2006-07-17 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Controlled degradation of stents |
US7886419B2 (en) * | 2006-07-18 | 2011-02-15 | Advanced Cardiovascular Systems, Inc. | Stent crimping apparatus and method |
US7833260B2 (en) * | 2006-07-20 | 2010-11-16 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
WO2008011614A2 (en) * | 2006-07-20 | 2008-01-24 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
EP2044140B1 (en) | 2006-07-20 | 2017-05-17 | OrbusNeich Medical, Inc. | Bioabsorbable polymeric composition for a medical device |
US8016879B2 (en) * | 2006-08-01 | 2011-09-13 | Abbott Cardiovascular Systems Inc. | Drug delivery after biodegradation of the stent scaffolding |
US20080091262A1 (en) * | 2006-10-17 | 2008-04-17 | Gale David C | Drug delivery after biodegradation of the stent scaffolding |
US20080033487A1 (en) * | 2006-08-07 | 2008-02-07 | Bioduct, Llc | Medical device for repair of tissue and method for implantation and fixation |
EP2051646A4 (en) * | 2006-08-07 | 2014-06-11 | Howmedica Osteonics Corp | Insertion system for implanting a medical device and surgical methods |
US9173733B1 (en) | 2006-08-21 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Tracheobronchial implantable medical device and methods of use |
US7923022B2 (en) * | 2006-09-13 | 2011-04-12 | Advanced Cardiovascular Systems, Inc. | Degradable polymeric implantable medical devices with continuous phase and discrete phase |
US9585989B2 (en) * | 2006-09-19 | 2017-03-07 | Boston Scientific Scimed, Inc. | Ureteral stent having variable hardness |
US7713308B2 (en) * | 2006-09-22 | 2010-05-11 | Boston Scientific Scimed, Inc. | Stent with soluble bladder retention member |
US7959942B2 (en) * | 2006-10-20 | 2011-06-14 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
WO2008070304A2 (en) * | 2006-10-20 | 2008-06-12 | Orbusneich Medical, Inc. | Bioabsorbable polymeric composition and medical device background |
US20080103584A1 (en) | 2006-10-25 | 2008-05-01 | Biosensors International Group | Temporal Intraluminal Stent, Methods of Making and Using |
US7943683B2 (en) * | 2006-12-01 | 2011-05-17 | Tepha, Inc. | Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers |
US8099849B2 (en) | 2006-12-13 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Optimizing fracture toughness of polymeric stent |
US20080243228A1 (en) * | 2007-03-28 | 2008-10-02 | Yunbing Wang | Implantable medical devices fabricated from block copolymers |
US8262723B2 (en) | 2007-04-09 | 2012-09-11 | Abbott Cardiovascular Systems Inc. | Implantable medical devices fabricated from polymer blends with star-block copolymers |
US7829008B2 (en) * | 2007-05-30 | 2010-11-09 | Abbott Cardiovascular Systems Inc. | Fabricating a stent from a blow molded tube |
US7959857B2 (en) * | 2007-06-01 | 2011-06-14 | Abbott Cardiovascular Systems Inc. | Radiation sterilization of medical devices |
US8202528B2 (en) * | 2007-06-05 | 2012-06-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices with elastomeric block copolymer coatings |
US8293260B2 (en) | 2007-06-05 | 2012-10-23 | Abbott Cardiovascular Systems Inc. | Elastomeric copolymer coatings containing poly (tetramethyl carbonate) for implantable medical devices |
US10590391B2 (en) * | 2007-06-08 | 2020-03-17 | Wake Forest University Health Sciences | Selective cell therapy for the treatment of renal failure |
AU2008262333B2 (en) * | 2007-06-08 | 2014-07-17 | Wake Forest University Health Sciences | Selective cell therapy for the treatment of renal failure |
US8425591B1 (en) | 2007-06-11 | 2013-04-23 | Abbott Cardiovascular Systems Inc. | Methods of forming polymer-bioceramic composite medical devices with bioceramic particles |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
US7901452B2 (en) * | 2007-06-27 | 2011-03-08 | Abbott Cardiovascular Systems Inc. | Method to fabricate a stent having selected morphology to reduce restenosis |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
US7955381B1 (en) | 2007-06-29 | 2011-06-07 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical device with different types of bioceramic particles |
US20110130822A1 (en) * | 2007-07-20 | 2011-06-02 | Orbusneich Medical, Inc. | Bioabsorbable Polymeric Compositions and Medical Devices |
US20100093946A1 (en) * | 2008-10-11 | 2010-04-15 | Orbusneich Medical, Inc. | Bioabsorbable Polymeric Compositions and Medical Devices |
US8661630B2 (en) | 2008-05-21 | 2014-03-04 | Abbott Cardiovascular Systems Inc. | Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer |
US20090306120A1 (en) * | 2007-10-23 | 2009-12-10 | Florencia Lim | Terpolymers containing lactide and glycolide |
US20090104241A1 (en) * | 2007-10-23 | 2009-04-23 | Pacetti Stephen D | Random amorphous terpolymer containing lactide and glycolide |
US20090110713A1 (en) * | 2007-10-31 | 2009-04-30 | Florencia Lim | Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices |
US8500947B2 (en) | 2007-11-15 | 2013-08-06 | Covidien Lp | Speeding cure rate of bioadhesives |
US8241657B2 (en) | 2007-12-04 | 2012-08-14 | Boston Scientific Scimed, Inc. | Biodisintegrable medical devices |
US7972373B2 (en) * | 2007-12-19 | 2011-07-05 | Advanced Technologies And Regenerative Medicine, Llc | Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts |
US8697113B2 (en) * | 2008-05-21 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Coating comprising a terpolymer comprising caprolactone and glycolide |
US8298466B1 (en) | 2008-06-27 | 2012-10-30 | Abbott Cardiovascular Systems Inc. | Method for fabricating medical devices with porous polymeric structures |
CN102245132A (en) * | 2008-10-10 | 2011-11-16 | 奥巴斯尼茨医学公司 | Bioabsorbable polymeric medical device |
GB0819296D0 (en) * | 2008-10-21 | 2008-11-26 | Smith & Nephew | Coating II |
CN102271692B (en) * | 2008-11-12 | 2014-05-21 | 坦吉恩股份有限公司 | Isolated renal cells and uses thereof |
WO2010057015A1 (en) * | 2008-11-14 | 2010-05-20 | Wake Forest University Health Sciences | Kidney structures and methods of forming the same |
US9492587B2 (en) * | 2009-04-13 | 2016-11-15 | Abbott Cardiovascular Systems Inc. | Stent made from an ultra high molecular weight bioabsorbable polymer with high fatigue and fracture resistance |
US8697110B2 (en) * | 2009-05-14 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Polymers comprising amorphous terpolymers and semicrystalline blocks |
US8119704B2 (en) * | 2009-07-21 | 2012-02-21 | Abbott Cardiovascular Systems Inc. | Implantable medical device comprising copolymer of L-lactide with improved fracture toughness |
US8568471B2 (en) | 2010-01-30 | 2013-10-29 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
US8808353B2 (en) | 2010-01-30 | 2014-08-19 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds having a low crossing profile |
US8496865B2 (en) | 2010-10-15 | 2013-07-30 | Abbott Cardiovascular Systems Inc. | Method to minimize chain scission and monomer generation in processing of poly(L-lactide) stent |
CN103298498B (en) | 2010-11-10 | 2017-12-08 | 因瑞金公司 | Ejection preparation for organ enhancing |
US8936635B2 (en) | 2011-03-23 | 2015-01-20 | Palmetto Pharmaceuticals Llc | Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents |
US8726483B2 (en) | 2011-07-29 | 2014-05-20 | Abbott Cardiovascular Systems Inc. | Methods for uniform crimping and deployment of a polymer scaffold |
US10940167B2 (en) | 2012-02-10 | 2021-03-09 | Cvdevices, Llc | Methods and uses of biological tissues for various stent and other medical applications |
EP2634198B1 (en) | 2012-03-02 | 2014-09-17 | Suntech Co., Ltd. | Copolymers containing phosphorylcholine groups and methods of preparing and using the same |
US20140074065A1 (en) * | 2012-09-07 | 2014-03-13 | Acclarent, Inc. | Bioabsorbable Spacers and Spacer Delivery Systems for Use in the Ear, Nose and Throat |
US9943298B2 (en) | 2012-10-19 | 2018-04-17 | Cook Medical Technologies Llc | Vascular closure with shape memory characteristic |
AU2014214700B2 (en) | 2013-02-11 | 2018-01-18 | Cook Medical Technologies Llc | Expandable support frame and medical device |
US20140275467A1 (en) | 2013-03-15 | 2014-09-18 | Ethicon, Inc. | Polylactone Polymers Prepared from Monol and Diol Polymerization Initiators Processing Two or More Carboxylic Acid Groups |
WO2015020527A1 (en) | 2013-08-09 | 2015-02-12 | Maastricht University | Biodegradable radiopaque stents and other implants |
US9381280B2 (en) | 2014-06-13 | 2016-07-05 | Abbott Cardiovascular Systems Inc. | Plasticizers for a biodegradable scaffolding and methods of forming same |
US10500303B2 (en) | 2014-08-15 | 2019-12-10 | Tepha, Inc. | Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof |
US10626521B2 (en) | 2014-12-11 | 2020-04-21 | Tepha, Inc. | Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof |
US9555155B2 (en) | 2014-12-11 | 2017-01-31 | Tepha, Inc. | Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof |
US9999527B2 (en) | 2015-02-11 | 2018-06-19 | Abbott Cardiovascular Systems Inc. | Scaffolds having radiopaque markers |
US9700443B2 (en) | 2015-06-12 | 2017-07-11 | Abbott Cardiovascular Systems Inc. | Methods for attaching a radiopaque marker to a scaffold |
JP6766046B2 (en) * | 2015-07-16 | 2020-10-07 | テルモ株式会社 | Stent with biodegradable stent base |
US11123372B2 (en) | 2016-07-29 | 2021-09-21 | Prokidney | Bioactive renal cells for the treatment of chronic kidney disease |
CN110229471B (en) * | 2018-03-05 | 2021-04-06 | 盛嘉伦橡塑(深圳)股份有限公司 | Biodegradable thermoplastic elastomer material and preparation method thereof |
DE102018133599A1 (en) | 2018-12-26 | 2020-07-02 | Sven Oberbach | Coronary anastomosis connector |
DE202018107428U1 (en) | 2018-12-26 | 2019-03-27 | Sven Oberbach | Coronary anastomosis connector |
DE202019101465U1 (en) | 2019-03-14 | 2019-03-28 | Sven Oberbach | New coronary anastomosis connector |
CN112516390B (en) * | 2020-10-14 | 2022-08-05 | 浙江中在医疗科技有限公司 | Degradable ureter stent |
CN112521734B (en) * | 2020-10-14 | 2023-03-31 | 浙江中在医疗科技有限公司 | Degradable medical elastomer material and application thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4045418A (en) * | 1975-01-28 | 1977-08-30 | Gulf Oil Corporation | Copolymers of D,L-lactide and epsilon caprolactone |
US4300565A (en) * | 1977-05-23 | 1981-11-17 | American Cyanamid Company | Synthetic polyester surgical articles |
US4212304A (en) * | 1978-04-07 | 1980-07-15 | Medical Engineering Corp. | Uretheral catheter stent |
US4379138A (en) * | 1981-12-28 | 1983-04-05 | Research Triangle Institute | Biodegradable polymers of lactones |
US4605730A (en) * | 1982-10-01 | 1986-08-12 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
US4700704A (en) * | 1982-10-01 | 1987-10-20 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
NZ205680A (en) * | 1982-10-01 | 1986-05-09 | Ethicon Inc | Glycolide/epsilon-caprolactone copolymers and sterile surgical articles made therefrom |
US4531933A (en) * | 1982-12-07 | 1985-07-30 | C. R. Bard, Inc. | Helical ureteral stent |
US4610657A (en) * | 1984-01-03 | 1986-09-09 | Medical Engineering Corporation | Ureteral stent |
US4650488A (en) * | 1984-05-16 | 1987-03-17 | Richards Medical Company | Biodegradable prosthetic device |
EP0183372A1 (en) * | 1984-10-19 | 1986-06-04 | RAYCHEM CORPORATION (a Delaware corporation) | Prosthetic stent |
US4674506A (en) * | 1984-11-29 | 1987-06-23 | Kirk Alcond | Surgical anastomosis stent |
FI81010C (en) * | 1986-09-05 | 1990-09-10 | Biocon Oy | Benomplaceringsimplants |
DE3785716T2 (en) * | 1986-09-23 | 1993-12-02 | American Cyanamid Co | Bioresorbable coating for surgical articles. |
IL82834A (en) * | 1987-06-09 | 1990-11-05 | Yissum Res Dev Co | Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom |
US4916193A (en) * | 1987-12-17 | 1990-04-10 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
US4874360A (en) * | 1988-07-01 | 1989-10-17 | Medical Engineering Corporation | Ureteral stent system |
US5076807A (en) * | 1989-07-31 | 1991-12-31 | Ethicon, Inc. | Random copolymers of p-dioxanone, lactide and/or glycolide as coating polymers for surgical filaments |
US4994074A (en) * | 1990-02-01 | 1991-02-19 | Ethicon, Inc. | Copolymers of ε-caprolactone, glycolide and glycolic acid for suture coatings |
-
1989
- 1989-09-27 US US07/414,651 patent/US5085629A/en not_active Expired - Lifetime
-
1990
- 1990-09-18 CA CA002025626A patent/CA2025626A1/en not_active Abandoned
- 1990-09-24 EP EP19900310418 patent/EP0420541A3/en not_active Withdrawn
- 1990-09-26 JP JP2254356A patent/JPH03205059A/en active Pending
- 1990-09-26 AU AU63643/90A patent/AU633361B2/en not_active Ceased
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6045568A (en) * | 1991-03-08 | 2000-04-04 | Igaki; Keiji | Luminal stent, holding structure therefor and device for attaching luminal stent |
USRE38653E1 (en) * | 1991-03-08 | 2004-11-16 | Kabushikikaisha Igaki Iryo Sekkei | Luminal stent, holding structure therefor and device for attaching luminal stent |
US5464450A (en) * | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
US5551954A (en) | 1991-10-04 | 1996-09-03 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5762625A (en) * | 1992-09-08 | 1998-06-09 | Kabushikikaisha Igaki Iryo Sekkei | Luminal stent and device for inserting luminal stent |
US5817100A (en) * | 1994-02-07 | 1998-10-06 | Kabushikikaisya Igaki Iryo Sekkei | Stent device and stent supplying system |
US7572287B2 (en) | 2001-10-25 | 2009-08-11 | Boston Scientific Scimed, Inc. | Balloon expandable polymer stent with reduced elastic recoil |
US6981985B2 (en) | 2002-01-22 | 2006-01-03 | Boston Scientific Scimed, Inc. | Stent bumper struts |
US7060089B2 (en) | 2002-01-23 | 2006-06-13 | Boston Scientific Scimed, Inc. | Multi-layer stent |
Also Published As
Publication number | Publication date |
---|---|
AU6364390A (en) | 1991-04-11 |
US5085629A (en) | 1992-02-04 |
EP0420541A3 (en) | 1992-04-22 |
AU633361B2 (en) | 1993-01-28 |
JPH03205059A (en) | 1991-09-06 |
EP0420541A2 (en) | 1991-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5085629A (en) | Biodegradable stent | |
US5486593A (en) | Medical devices fabricated from copolymers having recurring carbonate units | |
US4920203A (en) | Medical devices fabricated from homopolymers and copolymers having recurring carbonate units | |
US5152781A (en) | Medical devices fabricated from homopolymers and copolymers having recurring carbonate units | |
US5145945A (en) | Homopolymers and copolymers having recurring carbonate units | |
US5185408A (en) | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides | |
US4916193A (en) | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides | |
US5066772A (en) | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides | |
US6113624A (en) | Absorbable elastomeric polymer | |
Vert et al. | Stereoregular bioresorbable polyesters for orthopaedic surgery | |
EP1244725B1 (en) | Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom | |
AU662460B2 (en) | Elastomeric medical device | |
US5531998A (en) | Polycarbonate-based block copolymers and devices | |
US5047048A (en) | Crystalline copolymers of p-dioxanone and ε-caprolactone | |
US5061281A (en) | Bioresorbable polymers and implantation devices thereof | |
US4891263A (en) | Polycarbonate random copolymer-based fiber compositions and method of melt-spinning same and device | |
CA1255844A (en) | Radiation sterilizable absorbable polymeric materials and methods for manufacturing the same | |
JP4899152B2 (en) | MEDICAL RESIN COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND MOLDED ARTICLE | |
AU2003207416B2 (en) | DL-lactide-e-caprolactone copolymers | |
EP0390860B1 (en) | Medical devices fabricated from homopolymers and copolymers having recurring carbonate units | |
US5256764A (en) | Medical devices fabricated from homopolymers and copolymers having recurring carbonate units | |
EP1216132A2 (en) | A method of making biodegradable polymeric implants | |
EP1260533B1 (en) | High strengh fibers of i-lactide copolymers, e-caprolactone, and trimethylene carbonate and absorbable medical constructs thereof | |
US5492997A (en) | Copolymer of lactone and carbonate and process for the preparation of such a copolymer | |
Hyon et al. | Melt spinning of poly-L-lactide and hydrolysis of the fiber in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |